Race Oncology (ASX:RAC) secured around AU$1 million via a targeted private placement with a specialist healthcare-focused institutional investor, issuing 526,315 fully paid ordinary shares at AU$1.90 each, representing a 23% discount to its recent average market price, according to a Thursday filing with the Australian bourse.
The company has raised a total of AU$31.2 million, including this placement and recent funds from piggyback and bonus option offers, to support the clinical development of RC220 and general working capital requirements, the filing added.